200 related articles for article (PubMed ID: 24287066)
21. Evolution of radiation therapy within the German Hodgkin Study Group trials.
Eich HT; Kriz J; Müller RP
J Natl Compr Canc Netw; 2011 Sep; 9(9):1073-80. PubMed ID: 21917628
[TBL] [Abstract][Full Text] [Related]
22. Management of Adolescent Low-Risk Classical Hodgkin Lymphoma: Which Chemotherapy Backbone Gives the Best Chance of Omitting Radiotherapy Safely.
Algiraigri AH; Essa MF
J Adolesc Young Adult Oncol; 2016 Mar; 5(1):2-7. PubMed ID: 26812449
[TBL] [Abstract][Full Text] [Related]
23. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
[TBL] [Abstract][Full Text] [Related]
24. The role of PET in Hodgkin's lymphoma and its impact on radiation oncology.
Kobe C; Dietlein M; Kriz J; Furth C; Fuchs M; Borchmann P; Engert A; Eich HT
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1419-28. PubMed ID: 20836677
[TBL] [Abstract][Full Text] [Related]
25. Involved node radiation therapy: an effective alternative in early-stage hodgkin lymphoma.
Maraldo MV; Aznar MC; Vogelius IR; Petersen PM; Specht L
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1057-65. PubMed ID: 23200817
[TBL] [Abstract][Full Text] [Related]
26. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
[TBL] [Abstract][Full Text] [Related]
27. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.
Enrici RM; Anselmo AP; Donato V; Falchetto Osti M; Santoro M; Tombolini V; Mandelli F
Haematologica; 1999 Oct; 84(10):917-23. PubMed ID: 10509040
[TBL] [Abstract][Full Text] [Related]
28. Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 Trial.
Baues C; Goergen H; Fuchs M; Rosenbrock J; Celik E; Eich H; Kobe C; Voltin CA; Engert A; Borchmann P; Marnitz S
Int J Radiat Oncol Biol Phys; 2021 Nov; 111(4):900-906. PubMed ID: 34389407
[TBL] [Abstract][Full Text] [Related]
29. The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: evolution in the tradition of the DAL/GPOH studies.
Körholz D; Claviez A; Hasenclever D; Kluge R; Hirsch W; Kamprad F; Dörffel W; Wickmann L; Papsdorf K; Dieckmann K; Kahn T; Mauz-Körholz C; Dannenberg C; Pötter R; Brosteanu O; Schellong G; Sabri O
Klin Padiatr; 2004; 216(3):150-6. PubMed ID: 15175959
[TBL] [Abstract][Full Text] [Related]
30. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
[TBL] [Abstract][Full Text] [Related]
31. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM;
Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286
[TBL] [Abstract][Full Text] [Related]
32. Treatment of early-stage Hodgkin lymphoma.
Engert A; Raemaekers J
Semin Hematol; 2016 Jul; 53(3):165-70. PubMed ID: 27496307
[TBL] [Abstract][Full Text] [Related]
33. Combined-modality therapy for early-stage Hodgkin lymphoma: maintaining high cure rates while minimizing risks.
Kelsey CR; Beaven AW; Diehl LF; Prosnitz LR
Oncology (Williston Park); 2012 Dec; 26(12):1182-9, 1193. PubMed ID: 23413599
[TBL] [Abstract][Full Text] [Related]
34. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
Kedmi M; Apel A; Davidson T; Levi I; Dann EJ; Polliack A; Ben-Bassat I; Nagler A; Avigdor A
Acta Haematol; 2016; 135(3):156-61. PubMed ID: 26588173
[TBL] [Abstract][Full Text] [Related]
35. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Kontopidou FN; Dimopoulou MN; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Karkantaris C; Anargyrou K; Boutsis DE; Variamis E; Michalopoulos T; Boussiotis VA; Panayiotidis P; Papavassiliou C; Pangalis GA
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):765-81. PubMed ID: 15183480
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy only in early stage Hodgkin lymphoma: more relapses but the same survival--what to do?
Connors JM
Curr Hematol Malig Rep; 2014 Sep; 9(3):217-21. PubMed ID: 24838494
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy only in early-stage Hodgkin lymphoma: more relapses but "same" (or possibly worse) survival--reconsidering the misguided trend to omit radiotherapy.
Yahalom J
Curr Hematol Malig Rep; 2014 Sep; 9(3):212-6. PubMed ID: 24939521
[TBL] [Abstract][Full Text] [Related]
38. Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy.
Gobbi PG; Bassi E; Bergonzi M; Merli F; Coriani C; Iannitto E; Luminari S; Polimeno G; Federico M
Hematol Oncol; 2012 Dec; 30(4):194-9. PubMed ID: 22271092
[TBL] [Abstract][Full Text] [Related]
39. [Therapy of Hodgkin lymphoma: chances of remission are good, treatment tolerance needs improvement].
Bischoff M
MMW Fortschr Med; 2011 Oct; 153(41):17. PubMed ID: 22046834
[No Abstract] [Full Text] [Related]
40. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
